TY - JOUR T1 - Emergence of SARS-CoV-2 variants of concern in the pediatric population of the United States JF - medRxiv DO - 10.1101/2021.05.22.21257660 SP - 2021.05.22.21257660 AU - Jennifer Dien Bard AU - Moiz Bootwalla AU - Amy Leber AU - Paul Planet AU - Ahmed M. Moustafa AU - Rebecca Harris AU - Pei Ying Chen AU - Lishuang Shen AU - Dejerianne Ostrow AU - Dennis Maglinte AU - Jessica Flores AU - Roy Somak AU - Sarangarajan Ranganathan AU - Elizabeth Perlman AU - Xiaotian Zheng AU - Rangaraj Selvarangan AU - Meghan Delaney AU - Joseph Campos AU - Drew G. Michael AU - Eric Vilain AU - Jonathan LoTempio AU - James Dunn AU - Sarah Jung AU - Samuel Dominguez AU - Alexander R. Judkins AU - Xiaowu Gai Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/05/24/2021.05.22.21257660.abstract N2 - The evolution of SARS-CoV2 virus has led to the emergence of variants of concern (VOC). Children, particularly <12 years old not yet eligible for vaccines, continue to be important reservoirs of SARS-CoV-2 yet VOC prevalence data in this population is lacking. We report data from a genomic surveillance program that includes 9 U.S. children’s hospitals. Analysis of SARS-CoV-2 genomes from 2119 patients <19 years old between 03/20 to 04/21 identified 252 VOCs and 560 VOC signature mutations, most from 10/20 onwards. From 02/21 to 04/21, B.1.1.7 prevalence increased from 3.85% to 72.22% corresponding with the decline of B.1.429/B.1.427 from 51.82% to 16.67% at one institution. 71.74% of the VOC signature mutations detected were in children <12 years old, including 33 cases of B.1.1.7 and 119 of B.1.429/B.1.427. There continues to be a need for ongoing genomic surveillance, particularly among young children who will be the last groups to be vaccinated.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was partially funded by The Saban Research Institute at Children's Hospital Los Angeles intramural support for COVID-19 Directed ResearchAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the CHLA Institutional Review Board (CHLA-16-00429).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll genomic data were uploaded to GISAID. The corresponding accessions are available upon request from the corresponding author. ER -